Physician profile
Abhishek Pulla
NPI 1790179141
$3,522.46
in general payments reported to CMS, 2019-2025
26 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $513 · 2023: $986 · 2024: $907 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,823 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,823.12 |
| Education | $186.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $513.17 | 2022-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $257.55 | 2023-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $251.68 | 2024-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $206.59 | 2023-2024 | |
| Bard Peripheral Vascular, INC. | $201.77 | 2023-2025 | Covera |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $183.43 | 2023-2025 | Voyxact |
| Fresenius USA Marketing, INC. | $176.52 | 2023-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $174.47 | 2024-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $157.46 | 2022-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $154.75 | 2023-2025 | Rayaldee |
| Amgen INC. | $153.02 | 2024-2025 | Krystexxa, Tavneos |
| Medtronic, INC. | $143.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $139.51 | 2024-2025 | |
| Novo Nordisk INC | $128.81 | 2024-2025 | |
| Akebia Therapeutics INC | $128.52 | 2025 | Vafseo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $98.99 | 2022-2024 | Lupkynis |
| Ardelyx, INC. | $98.37 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.33 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $71.57 | 2022-2024 | |
| Vifor Pharma, INC. | $57.33 | 2022-2023 | Veltassa |
| Alexion Pharmaceuticals, INC. | $27.23 | 2024 | Ultomiris |
| Scpharmaceuticals INC. | $24.58 | 2025 | |
| Apellis Pharmaceuticals, INC. | $24.24 | 2025 | |
| Daiichi Sankyo INC. | $22.98 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.31 | 2025 | Keveyis |
| Glaxosmithkline, LLC. | $16.08 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhishek Pulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.